TNF and Alzheimer disease: This indicates that blocking peripheral TNF alone may be insufficient, potentially requiring combination with BBB‐penetrating agents or direct targeting of specific TNF forms (e.g., soluble TNF) [675]; a Phase II clinical trial (NCT05318976) indicates that XPro1595, a selective soluble TNF inhibitor, demonstrates potential in early AD trials.